Market Overview:
The global Enbrel market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of autoimmune diseases, increasing demand for biosimilar drugs and growing awareness about treatment options for autoimmune diseases. The global Enbrel market is segmented on the basis of type, application and region. On the basis of type, it is segmented into brands drugs and biosimilar drugs. On the basis of application, it is segmented into rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and other applications. The RA segment accounts for majority share in terms of revenue in 2017 and is expected to maintain its dominance during the forecast period from 2018 to 2030 owing to high prevalence rate of RA across globe. However, AS segment is projected to grow at highest CAGR during forecast period owing increasing incidence rateof AS across globe coupled with introductionof novel therapies such as certolizumab pegol (Cimzia).
Product Definition:
ENBREL is a prescription medication used to treat adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. ENBREL can decrease joint pain and swelling, help you move more easily, and improve your quality of life.
Brands Drugs:
Brands drugs are the most lucrative drugs in a market. They have more than three times the revenue of any other drug and this is driving their growth in Enbrel market.
Brands Drugs are biologics and they have attributes that set them apart from generics such as fewer side effects, higher efficacy, greater convenience, etc.
Biosimilar Drugs:
Biosimilars are biological drugs that are highly similar to branded drugs. They have the same active ingredients as branded molecules, but they are manufactured using cheaper raw materials and in lesser quantities hence they cost much less than the original drug. The main objective of developing biosimilars is to reduce healthcare expenditure worldwide by reducing the price of patented pharmaceuticals.
Application Insights:
Rheumatoid arthritis held the largest share of over 40.0% in 2017. The presence of effective therapies, such as methotrexate, hydroxychloroquine and sulfasalazine for the treatment of rheumatoid arthritis has fueled its demand worldwide. Methotrexate is an anti-inflammatory drug which is used for treating various types of arthritis including juvenile idiopathic Arthritis (JIA), osteoarthritis, and rheumatoid arthritis. Enbrel biosimilars are expected to gain traction in the coming years owing to their ability to reduce pain & inflammation along with improving joint mobility & function at a lower cost than Enbrel original brand drugs do.
Psoriatic arthritis was one among other applications that shared a smaller market share in 2017 due largely to low penetration rate compared to other applications such as ankylosing spondylitis and JIA.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position throughout the forecast period owing to high awareness levels and availability of effective treatment options for arthritis. In addition, increasing R&D activities by major companies and rising healthcare expenditure are also contributing towards growth in this region.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to improving healthcare infrastructure, growing patient awareness levels about available treatment options, economic development coupled with government initiatives & support for quality medical care services & facilities (acute & chronic diseases). These factors are likely to contribute towards a positive outlook for the ENBREL market during the forecast period from 2018 to 2030 in Asia Pacific as well as other regions where biosimilars are approved such as Europe and Latin America countries.
The key markets analyzed in this study include Germany, France, Italy, U.K.
Growth Factors:
- Increasing incidence of autoimmune diseases: The global prevalence of autoimmune diseases is increasing at an alarming rate. This is expected to drive the demand for Enbrel and other TNF inhibitors in the coming years.
- Growing awareness about Enbrel and its benefits: There is a growing awareness among physicians and patients about the benefits of Enbrel therapy. This is likely to boost demand for the drug in the coming years.
- Launch of new indications: The manufacturers are constantly launching new indications for Enbrel, which is expected to fuel market growth in the coming years.
- Rising number of product approvals: The number of product approvals for Enbrel has been rising steadily over the past few years, indicating growing acceptance among physicians and patients alike. This trend is likely to continue in future, boosting market growth prospects further.. 5) Availability of generic versions: A number if generic versions are available in key markets across the globe, which could restrain market growth to some extent
Scope Of The Report
Report Attributes
Report Details
Report Title
Enbrel Market Research Report
By Type
Brands Drugs, Biosimilar Drugs
By Application
Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Other
By Companies
Amgen, Pfizer, 3SBIO, Celgen Biopharma, Amgen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
123
Number of Tables & Figures
87
Customization Available
Yes, the report can be customized as per your need.
Global Enbrel Market Report Segments:
The global Enbrel market is segmented on the basis of:
Types
Brands Drugs, Biosimilar Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen
- Pfizer
- 3SBIO
- Celgen Biopharma
- Amgen
Highlights of The Enbrel Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Brands Drugs
- Biosimilar Drugs
- By Application:
- Rheumatoid Arthritis
- Juvenile Idiopathic Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Enbrel Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Enbrel is a medication used to treat rheumatoid arthritis. It works by stopping the inflammation and pain that is caused by the disease.
Some of the key players operating in the enbrel market are Amgen, Pfizer, 3SBIO, Celgen Biopharma, Amgen.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Enbrel Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Enbrel Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Enbrel Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Enbrel Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Enbrel Market Size & Forecast, 2018-2028
4.5.1 Enbrel Market Size and Y-o-Y Growth
4.5.2 Enbrel Market Absolute $ Opportunity
Chapter 5 Global Enbrel Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Enbrel Market Size Forecast by Type
5.2.1 Brands Drugs
5.2.2 Biosimilar Drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Enbrel Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Enbrel Market Size Forecast by Applications
6.2.1 Rheumatoid Arthritis
6.2.2 Juvenile Idiopathic Arthritis
6.2.3 Psoriatic Arthritis
6.2.4 Ankylosing Spondylitis
6.2.5 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Enbrel Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Enbrel Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Enbrel Analysis and Forecast
9.1 Introduction
9.2 North America Enbrel Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Enbrel Market Size Forecast by Type
9.6.1 Brands Drugs
9.6.2 Biosimilar Drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Enbrel Market Size Forecast by Applications
9.10.1 Rheumatoid Arthritis
9.10.2 Juvenile Idiopathic Arthritis
9.10.3 Psoriatic Arthritis
9.10.4 Ankylosing Spondylitis
9.10.5 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Enbrel Analysis and Forecast
10.1 Introduction
10.2 Europe Enbrel Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Enbrel Market Size Forecast by Type
10.6.1 Brands Drugs
10.6.2 Biosimilar Drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Enbrel Market Size Forecast by Applications
10.10.1 Rheumatoid Arthritis
10.10.2 Juvenile Idiopathic Arthritis
10.10.3 Psoriatic Arthritis
10.10.4 Ankylosing Spondylitis
10.10.5 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Enbrel Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Enbrel Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Enbrel Market Size Forecast by Type
11.6.1 Brands Drugs
11.6.2 Biosimilar Drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Enbrel Market Size Forecast by Applications
11.10.1 Rheumatoid Arthritis
11.10.2 Juvenile Idiopathic Arthritis
11.10.3 Psoriatic Arthritis
11.10.4 Ankylosing Spondylitis
11.10.5 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Enbrel Analysis and Forecast
12.1 Introduction
12.2 Latin America Enbrel Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Enbrel Market Size Forecast by Type
12.6.1 Brands Drugs
12.6.2 Biosimilar Drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Enbrel Market Size Forecast by Applications
12.10.1 Rheumatoid Arthritis
12.10.2 Juvenile Idiopathic Arthritis
12.10.3 Psoriatic Arthritis
12.10.4 Ankylosing Spondylitis
12.10.5 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Enbrel Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Enbrel Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Enbrel Market Size Forecast by Type
13.6.1 Brands Drugs
13.6.2 Biosimilar Drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Enbrel Market Size Forecast by Applications
13.10.1 Rheumatoid Arthritis
13.10.2 Juvenile Idiopathic Arthritis
13.10.3 Psoriatic Arthritis
13.10.4 Ankylosing Spondylitis
13.10.5 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Enbrel Market: Competitive Dashboard
14.2 Global Enbrel Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen
14.3.2 Pfizer
14.3.3 3SBIO
14.3.4 Celgen Biopharma
14.3.5 Amgen
